Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Evommune Inc (EVMN)

Evommune Inc (EVMN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 852,546
  • Shares Outstanding, K 36,018
  • Annual Sales, $ 13,000 K
  • Annual Income, $ -68,870 K
  • EBIT $ -30 M
  • EBITDA $ -28 M
  • 60-Month Beta N/A
  • Price/Sales 64.08
  • Price/Cash Flow N/A
  • Price/Book 3.55

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate -0.72
  • Number of Estimates 6
  • High Estimate -0.55
  • Low Estimate -0.83
  • Prior Year N/A
  • Growth Rate Est. (year over year) -100.07%

Price Performance

See More
Period Period Low Period High Performance
1-Month
20.64 +7.46%
on 03/24/26
27.58 -19.59%
on 03/06/26
-3.82 (-14.69%)
since 02/27/26
3-Month
14.77 +50.17%
on 01/05/26
33.20 -33.19%
on 02/10/26
+4.97 (+28.88%)
since 12/26/25

Most Recent Stories

More News
Evommune Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Highlights

– Reported positive top-line data from Phase 2a proof-of-concept (POC) trial of EVO301 in atopic dermatitis (AD) – EVO756 on track to report Phase 2b top-line data...

EVMN : 22.18 (-6.29%)
Evommune Announces $125 Million Private Placement

Evommune, Inc. (“Evommune” or the “Company”) (NYSE: EVMN), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today...

EVMN : 22.18 (-6.29%)
Evommune Announces Positive Top-line Data from Phase 2a Proof-of-Concept Trial of EVO301 in Moderate-to-Severe Atopic Dermatitis

- Trial met primary efficacy endpoint at week 12 - EVO301 produced rapid, statistically significant EASI reductions at weeks 4, 8 and 12 versus placebo ...

EVMN : 22.18 (-6.29%)
High Risk, High Reward: 3 Healthcare Stocks to Watch in 2026

2026 could be a pivotal year for three biotech names, including a standout in the hemodialysis space and two emerging companies with strong pipelines.

EVMN : 22.18 (-6.29%)
ATAI : 3.35 (-5.37%)
CRMD : 6.71 (+0.15%)
Evommune Reports Third Quarter 2025 Financial Results and Provides Business Update

- Three Phase 2 data readouts from lead programs, EVO756 and EVO301, expected in 2026 across atopic dermatitis (AD) and chronic spontaneous urticaria (CSU) - Well capitalized...

EVMN : 22.18 (-6.29%)
Evommune Announces Pricing of its Initial Public Offering

PALO ALTO, Calif. , Nov. 5, 2025 /PRNewswire/ -- Evommune, Inc. ("Evommune"), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory...

EVMN : 22.18 (-6.29%)
Evommune Announces Commencement of Initial Public Offering

PALO ALTO, Calif. , Oct. 30, 2025 /PRNewswire/ -- Evommune, Inc. ("Evommune"), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory...

EVMN : 22.18 (-6.29%)

Business Summary

Evommune Inc. is a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases. Evommune Inc. is based in PALO ALTO, Calif.

See More

Key Turning Points

3rd Resistance Point 24.59
2nd Resistance Point 24.11
1st Resistance Point 23.14
Last Price 22.18
1st Support Level 21.70
2nd Support Level 21.22
3rd Support Level 20.25

See More

52-Week High 33.20
Fibonacci 61.8% 25.82
Fibonacci 50% 23.54
Last Price 22.18
Fibonacci 38.2% 21.26
52-Week Low 13.89

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.